Table 1.
Patient and disease characteristics of the analyzed cohort, stratified by radiotherapeutic modality*.
| Characteristic | SBRT | TARE | CRT | P |
|---|---|---|---|---|
| n (%) | 27 (100%) | 60 (100%) | 54 (100%) | |
| Age (Years) | ||||
| Median (IQR) | 71 (61, 80) | 65 (57.5, 74.5) | 67 (61, 74) | 0.11† |
| Sex | ||||
| Male | 18 (66.7%) | 27 (45.0%) | 25 (46.3%) | 0.14‡ |
| Female | 9 (33.3%) | 33 (55.0%) | 29 (53.7%) | |
| Race | ||||
| White | 25 (92.6%) | 51 (85.0%) | 46 (85.2%) | |
| Black | 1 (3.7%) | 2 (3.3%) | 2 (3.7%) | 0.85§ |
| Other | 1 (3.7%) | 7 (11.7%) | 6 (11.1%) | |
| Charlson Comorbidity Score | ||||
| 0 | 17 (63.0%) | 41 (68.3%) | 39 (72.2%) | 0.35§ |
| 1 | 9 (33.3%) | 13 (21.7%) | 14 (25.9%) | |
| 2 | 1 (3.7%) | 6 (10.0%) | 1 (1.9%) | |
| Year of diagnosis | ||||
| Median (IQR) | 2011 (2008, 2013) | 2013 (2011, 2014) | 2010 (2007, 2012) | <0.0001† |
| T-stage | ||||
| 1 | 16 (59.3%) | 18 (30.0%) | 13 (24.1%) | |
| 2 | 7 (25.9%) | 34 (56.7%) | 15 (27.8%) | <0.0001§ |
| 3 | 3 (11.1%) | 8 (13.3%) | 22 (40.7%) | |
| 4 | 1 (3.7%) | 0 (0.0%) | 4 (7.4%) | |
| Tumor Size (cm) | ||||
| Median (IQR) | 4.5 (3.2, 5.9) | 6.5 (4.5, 9.2) | 4.4 (2.9, 6.5) | <0.0001† |
| Vascular Invasion | ||||
| No | 16 (59.3%) | 23 (38.3%) | 12 (22.2%) | 0.038‡ |
| Yes | 7 (25.9%) | 21 (35.0%) | 22 (40.7%) | |
| Unknown | 4 (14.8%) | 16 (26.7%) | 20 (37.0%) | |
| Tumor Focality | ||||
| Unifocal | 3 (11.1%) | 19 (31.7%) | 3 (5.6%) | 0.032§ |
| Multifocal | 17 (63.0%) | 34 (56.7%) | 24 (44.4%) | |
| Unknown | 7 (25.9%) | 7 (11.6%) | 27 (50.0%) | |
| Chemotherapy | ||||
| No | 16 (59.3%) | 27 (45.0%) | 0 (0.0%) | |
| Yes | 11 (40.7%) | 32 (53.3%) | 54 (100.0%) | |
| Unknown | 0 (%) | 1 (1.7%) | 0 (0.0%) | <0.0001§ |
*
Abbreviations. SBRT- stereotactic body radiation therapy. TARE- transarterial radioembolization. CRT- chemoradiation. IQR- Interquartile range.
†
Mann-Whitney U (Wilcoxon rank-sum) test.
‡
Chi-square test.
§
Fisher’s exact test.